{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}],"title":"CR"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"VPR"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"PR"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Relapsed"},{"measurements":[{"groupId":"OG000","value":"9"}],"title":"Not Assessed"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"Complete Response (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow.\n\nVery Good Partial Response (VGPR): Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \\< 100mg per 24-h.\n\nPartial Response (PR): \\> 50% reduction of serum M-protein and reduction in 24-h urinary M-protein by \\> 90% or to \\< 200mg per 24-h In addition to the above listed criteria, if present at baseline, a . 50% reduction in the size of soft tissue plasmacytomas is also required.\n\nStable Disease (SD): Not meeting criteria for CR, VGPR, PR or progressive disease.\n\nRelapse: Any of the following: Reappearance of serum or urine M-protein by immunofixation or electrophoresis Development of \\> 5% plasma cells in the bone marrow. Appearance of any other sign of progression (i.e., new plasmacytoma, lytic bone lesion)","groups":[{"description":"Patients receive high-dose melphalan IV 200mg/m\\^2 over 30 minutes on days -2 and -1 and undergo autologous peripheral blood stem cell transplantation (Minimum dose of 2 X 10(6) CD34 + cells/kg ) on day 0. Patients receive filgrastim 5ug/kg IV or SQ beginning on day 5 and continuing until blood counts recover. Beginning 4 to 8 weeks after transplantation, patients receive maintenance therapy comprising 1.3 mg/m\\^2 of bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive 40mg of oral dexamethasone on days 1 to 4. Treatment with dexamethasone repeats every month for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of bortezomib, patients receive 50mg/day of oral thalidomide once daily until disease progression.","id":"OG000","title":"Treatment (Stem Cell Transplant, Maintenance Treatment)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Five patients did not start the maintenance phase of the study because of neurotoxicity (n=3), thrombocytopenia (n=1), or withdrawal of consent (n=1).","reportingStatus":"POSTED","timeFrame":"Post-Thalidomide at 1 year.","title":"Count of Response in Patients Started on Maintenance Therapy","type":"SECONDARY","unitOfMeasure":"Participants"}